Dosing

Hulio® has been approved for the treatment of immune-mediated conditions in children and adults. The dosage of Hulio® in adults depends on the immune-mediated condition, they are being treated for. In children, dosage depends on their body weight too.

Please refer to the SmPC for full prescribing information.

Dosing in Adults

Adult indications Dosing
Rheumatoid arthritis 40 mg every alternate week as a single dose
Axial spondyloarthritis 40 mg every alternate week as a single dose
Psoriatic arthritis 40 mg every alternate week as a single dose
Hidradenitis suppurativa (HS) 160 mg initially at Day 1 followed by 80 mg two weeks later at Day 15. Two weeks later continue with a dose of 40 mg every week or 80 mg every other week
Crohn’s disease Initial dose of 80 mg followed by 40 mg every alternate week
Ulcerative colitis 160 mg at week 0 followed by 80 mg at week 2
Uveitis Initial dose of 80 mg followed by 40 mg every alternate week

Dosing in Children

  Patient Weight Dosing Regimen
Juvenile idiopathic arthritis 10 kg to < 30 kg 20 mg every other week
≥ 30 kg 40 mg every other week
Paediatric plaque psoriasis 15 kg to < 30 kg Initial dose of 20 mg, followed by 20 mg given every other week starting one week after the initial dose
≥ 30 kg Initial dose of 40 mg, followed by 40 mg given every other week starting one week after the initial dose
Adolescent hidradenitis suppurativa 80 mg at week 0 followed by 40 mg every other week starting at week 1 via subcutaneous injection.
Crohn’s disease < 40 kg 40 mg at week 0 and 20 mg at week 2 In case there is a need for a more rapid response to therapy with the awareness that the risk for adverse events may be higher with use of the higher induction dose, the following dose may be used:
80 mg at week 0 and 40 mg at week 2
≥ 40 kg 80 mg at week 0 and 40 mg at week 2 In case there is a need for a more rapid response to therapy with the awareness that the risk for adverse events may be higher with use of the higher induction dose, the following dose may be used:
160 mg at week 0 and 80 mg at week 2
Uveitis < 30 kg 20 mg every other week in combination with methotrexate
≥ 30 kg 40 mg every other week in combination with methotrexate

Restricted access

The website you are trying to access is designed for healthcare professionals only - the content is not designed for the general public.

Are you a healthcare professional based in UK or Ireland?

YES
NO

Report side effects

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare providers are asked to report any suspected adverse reactions. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. In order to support effective tracking and traceability of biologics including biosimilars, it is recommended that the brand name and batch number are recorded and used when reporting adverse events.

You are now leaving the Hulio® uk website